Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has approved insulin efsitora alfa-gobe (Onswik), a once-weekly basal insulin, to improve glycemic control in adults with 

, based on 4 phase 3 QWINT trials, Eli Lilly and Company announced on September 24, 2026.¹

According to Eli Lilly, efsitora is designed to maintain steady basal insulin levels across a full 7-day dosing interval, reducing basal injections from approximately 365 to 52 per year vs once-daily basal insulin. The US decision is the fourth global approval for efsitora in type 2 diabetes, following actions in the European Union, Mexico, and Japan.¹

"For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes," said Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health. "Onswik offers a new once-weekly basal insulin option for patients and reflects our continued commitment to deliver innovative treatment options that expand choice and provide greater flexibility in how people manage type 2 diabetes."

Insulin efsitora efficacy across the QWINT phase 3 trials

What is insulin efsitora alfa-gobe (Onswik) approved for?


Efsitora is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not indicated for type 1 diabetes, and its safety and efficacy in children have not been established.


Efsitora is injected subcutaneously once weekly on the same day each week. In QWINT-1, insulin-naive adults started at 100 U weekly with fixed escalations to 150 U, 250 U, and 400 U every 4 weeks as needed.

Across 4 phase 3 trials in more than 3,400 adults, once-weekly efsitora achieved noninferior HbA1c reductions vs once-daily glargine U-100 or degludec U-100. Level 2 or 3 hypoglycemia was lower with efsitora in QWINT-1 and not significantly different from comparators in QWINT-2, QWINT-3, and QWINT-4.

The QWINT program comprised 4 randomized, open-label registration trials comparing once-weekly efsitora with once-daily insulin glargine U-100 or insulin degludec U-100 in more than 3,400 insulin-naive and insulin-experienced adults.¹ Each trial met its primary end point of noninferior hemoglobin A1c (HbA1c) reduction from baseline, with a prespecified noninferiority margin of 0.4 percentage points.¹⁻⁵

In QWINT-1 (N = 795), insulin-naive participants started efsitora at 100 U weekly.² Doses escalated every 4 weeks, as needed, through fixed steps of 150 U, 250 U, and 400 U toward a fasting glucose goal of 80 to 130 mg/dL.² At week 52, HbA1c fell by 1.19 percentage points with efsitora and 1.16 percentage points with glargine (estimated treatment difference [ETD], −0.03 percentage points; 95% CI, −0.18 to 0.12).²

Participants receiving efsitora required a median of 2 dose adjustments, compared with 8 for glargine.² QWINT-2 (N = 928) enrolled insulin-naive adults with or without glucagon-like peptide-1 (GLP-1) receptor agonist therapy.³ At week 52, efsitora reduced HbA1c by 1.26 percentage points vs 1.17 percentage points with degludec (ETD, −0.09 percentage points; 95% CI, −0.22 to 0.04).³

In QWINT-3 (N = 986), adults already treated with basal insulin achieved HbA1c reductions of 0.81 vs 0.72 percentage points at week 26 (ETD, −0.09 percentage points; 95% CI, −0.19 to 0.01).⁴

QWINT-4 (N = 730) enrolled adults on basal-bolus regimens, pairing efsitora or glargine with prandial insulin lispro.⁵ From a baseline HbA1c of 8.18% in both groups, HbA1c fell by 1.01 percentage points with efsitora and 1.00 percentage points with glargine at week 26, establishing noninferiority.⁵

Efsitora Hypoglycemia Rates and Safety Profile

In QWINT-1, efsitora produced 0.50 combined level 2 or level 3 hypoglycemia events per participant-year vs 0.88 with glargine (estimated rate ratio [ERR], 0.57; 95% CI, 0.39–0.84).² In QWINT-2, rates were 0.58 vs 0.45 events per participant-year with degludec (ERR, 1.30; 95% CI, 0.94–1.78), with no severe episodes reported for efsitora and 6 for degludec.³

Through 78 weeks of QWINT-3, the level 2 or 3 hypoglycemia rate was 0.84 vs 0.74 events per patient-year of exposure (ERR, 1.14; 95% CI, 0.83–1.56; P = .43).⁴ Serious adverse events occurred in 16% (103/655) of efsitora recipients and 11% (37/331) of degludec recipients, primarily cardiovascular events in both groups.⁴ Time in range (70–180 mg/dL) during weeks 48 to 52 of QWINT-2 was 64.3% with efsitora vs 61.2% with degludec (ETD, 3.1 percentage points; 95% CI, 0.1–6.1).³

In the basal-bolus population of QWINT-4, level 2 or 3 hypoglycemia rates were 6.6 vs 5.9 events per patient-year of exposure (ERR, 1.11; 95% CI, 0.85–1.44; 

 = .44). Nocturnal event rates were 0.67 vs 1.00 events per patient-year (ERR, 0.67; 95% CI, 0.44–1.01; 

= .058).⁵ Serious adverse events occurred in 7% (25/365) of efsitora recipients and 6% (23/365) of glargine recipients.⁵

According to Eli Lilly, efsitora demonstrated an overall safety profile similar to the daily basal insulins studied. The label advises against use in type 1 diabetes due to increased risk of severe hypoglycemia and includes warnings for hypokalemia and for heart failure with concomitant thiazolidinedione use.¹ 

Common adverse reactions include hypoglycemia, hypersensitivity reactions, injection site reactions, lipodystrophy, pruritus, rash, peripheral edema, and weight gain.¹

The Onswik KwikPen will reach the US market in the coming months in 2 concentrations, U-500 (1,500 units per pen) and U-1,000 (3,000 units per pen). The U-500 pen delivers up to 400 units per injection in 5-unit increments, while the U-1,000 pen delivers up to 800 units in 10-unit increments.¹

Eli Lilly and Company. U.S. Food and Drug Administration (FDA) approves Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes. Published September 24, 2026. Accessed September 24, 2026. 

https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-fda-approves-lillys-onswiktm

Rosenstock J, Bailey T, Connery L, et al. Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med. 2025;393(4):325-335. doi:10.1056/NEJMoa2502796

Wysham C, Bajaj HS, Del Prato S, et al. Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. N Engl J Med. 2024;391(23):2201-2211. doi:10.1056/NEJMoa2403953

Philis-Tsimikas A, Bergenstal RM, Bailey TS, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2279-2289. doi:10.1016/S0140-6736(25)01044-X

Blevins T, Dahl D, Pérez Manghi FC, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2290-2301. doi:10.1016/S0140-6736(25)01069-4

Articles

FDA approval of once-weekly insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes was supported by four phase 3 QWINT trials (n>3,400) demonstrating noninferior HbA1c lowering versus insulin glargine U-100 or degludec U-100 across insulin-naive, basal-insulin–treated, and basal-bolus populations. Efsitora is engineered for stable 7-day basal coverage, potentially reducing annual basal injections from ~365 to 52. Safety was broadly comparable to daily basals, with expected insulin-class risks and specific label warnings.

FDA clears Eli Lilly’s Onswik weekly insulin from QWINT trials, cutting injections for type 2 diabetes while matching daily basal control.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Type 2 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


FDA News

Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes

Carlos Bacino, MD, is the medical director of the cytogenetics laboratory at Baylor Genetics.

This episode, titled “Redefining Treatment Success in Achondroplasia Beyond Height,” features panelists discussing how treatment goals in achondroplasia are expanding beyond linear growth. The panel begins by considering how the multisystem complications of achondroplasia affect mobility and daily function. Abnormal body proportions and skeletal development can influence gait, stamina, and the ability to navigate environments designed for average-statured individuals. These challenges underscore why a change in height alone may not fully capture meaningful clinical benefit.

Redefining Treatment Success in Achondroplasia Beyond Height

The experts discuss annualized growth velocity as a practical and readily measurable endpoint, while emphasizing that treatment success should also account for outcomes that may take longer to demonstrate. These include body proportionality, spinal and skeletal health, physical function, stamina, and the ability to participate more independently in everyday activities.

The panel also highlights the family perspective. Rather than focusing exclusively on achieving a particular height, many families prioritize helping their child remain healthy, function effectively, and become as independent as possible into adulthood. That broader view reframes treatment as an opportunity to support overall health and daily participation rather than simply changing stature. By establishing these broader treatment goals, the panel sets the stage for evaluating both available and emerging therapies according to outcomes that may be more meaningful to patients and families over the long term.

In the next episode, “Deciding When to Start Treatment in Achondroplasia,” panelists will discuss when treatment should begin and which therapies are currently available. They will also consider the potential benefits of earlier intervention alongside the practical and psychosocial burden of long-term treatment.

Videos

Height alone does not capture the full impact of achondroplasia. The panel discusses why health, function, proportionality, and independence are increasingly important measures of treatment success.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

In “Recognizing the Multisystem Burden of Achondroplasia,” our panel explores the clinical manifestations and complications that make achondroplasia much more than a disorder of short stature. The discussion begins with the experience of families receiving an unexpected diagnosis, particularly because many children with achondroplasia are born to parents without a prior family history of the condition. The panel emphasizes the importance of early education while avoiding overwhelming families with too much information at once.

Recognizing the Multisystem Burden of Achondroplasia

Particular attention is given to complications involving the skull base. The experts explain that foramen magnum narrowing is an important concern in infancy because severe stenosis can compress the brainstem or spinal cord and affect movement or breathing. In some children, surgical decompression may be required. The panel also discusses the potential for hydrocephalus and the importance of monitoring head circumference, fontanelle findings, and development.

Moving anteriorly, midface hypoplasia can contribute to eustachian tube dysfunction, recurrent otitis media, hearing impairment, and subsequent effects on language development. Adenoid and tonsillar crowding may also increase the risk of obstructive sleep apnea across infancy, childhood, and adulthood. Throughout the discussion, the panel stresses the value of structured surveillance and early education. Children with achondroplasia can be followed much like other children, but they require additional monitoring targeted to the known complications associated with the condition.

Our next episode, “Redefining Treatment Success in Achondroplasia Beyond Height,” shifts the discussion from disease burden to treatment goals. The panel will consider which outcomes matter most to clinicians, patients, and families when evaluating whether treatment is successful.

Beyond short stature, achondroplasia carries life-threatening risks at the skull base. The panel details why foramen magnum stenosis, hydrocephalus, and airway obstruction demand vigilant monitoring from infancy onward.

Building trust with patients who have diverse skin tones, and addressing 

 as a condition that reaches beyond the skin, were the focus of this segment of the most recent 

featuring Jennifer Soung, MD, and Mona Shahriari, MD.

Soung is known for her work as a board-certified dermatologist and as the director of clinical research at Southern California Dermatology in Santa Ana, California. Shahriari is an associate clinical professor of dermatology at Yale University and the host of HCPLive’s 

 podcast. Both spoke in this new episode of Skin of Colorsavvy, a podcast hosted by 

Why Trust and Timing Shape Psoriasis Outcomes in Skin of Color

Why Does Early Psoriasis Diagnosis Matter?

Shahriari opened by asking how clinicians can get patients into the office sooner for an accurate diagnosis, noting that delayed diagnosis in patients with diverse skin tones can leave disease harder to treat and less likely to reach remission. Soung said the current health care system is largely built around catastrophic care, responding once a patient has extensive body surface area involvement or can no longer work, rather than intervening early. She noted that early treatment improves outcomes across skin tones, but patients with diverse skin tones often face additional barriers to access and may distrust the health care system.

Soung said addressing that gap starts with meeting patients in their communities and building trust through cultural curiosity, including simple open-ended questions about a patient's skincare routines or cultural background. She described using telehealth in her own practice to reduce travel time and time away from work for patients, calling personalized, culturally sensitive care the future of the specialty.

How Can Clinicians Build Trust With Diverse Patient Populations?

Shahriari said patients increasingly assume a shared background signals expertise in treating their skin, recalling a patient who told her she must understand his skin because she looked like him. She said that assumption can be leveraged productively, but clinicians without shared backgrounds can build similar trust through curiosity and cultural sensitivity rather than assumed cultural knowledge. Both agreed that as demographics shift, patients with diverse skin tones will represent a growing share of dermatology practices, making early, trust-based diagnosis increasingly important to patient outcomes.

What Psychosocial Burdens Should Clinicians Watch For?

Shahriari asked how Soung addresses the psychosocial impact of psoriasis and connects patients with mental health support when needed. Soung said she now opens visits by asking patients how psoriasis has affected them, a question that can prompt strong emotional responses, including embarrassment and social stigma tied to visible plaques. She described a patient in his mid-30s who avoided removing his shirt at the beach for years until a stranger, noticing his discomfort, urged him to see a dermatologist.

Soung said moments like that reflect why many clinicians entered medicine, the ability to help patients feel normal again through connection and collaboration. Shahriari said she sometimes splits diagnosis and broader psoriasis-related counseling across separate visits so patients are not overwhelmed by comorbidity discussions on day one, an approach her schedule as a practice owner allows her the flexibility to offer.

How Should Treatment Plans Account for Patient Routines?

Soung noted that patients are often reluctant to admit dissatisfaction with an otherwise effective treatment unless directly asked, and that she has learned the most by asking patients at follow-up visits whether they are happy with their treatment. Shahriari raised the example of scalp psoriasis treatments that require daily shampoo use, noting that regimen is often unrealistic for patients with afro-textured or tightly coiled hair, and asked how treatment routes can better match a patient's daily routine and long-term adherence. Both agreed that efficacy alone does not determine whether a patient continues a treatment, and that the confidence and trust built during a visit often shape treatment success as much as the medication itself.

Editor's note: This summary was edited with the help of AI tools.

Soung J, Shahriari M. Skin of Color Savvy: Advice on Diagnosing Psoriasis in Diverse Skin Tones. HCPLive. August 26, 2026. Accessed September 22, 2026. 

https://www.hcplive.com/view/skin-color-savvy-advice-diagnosing-psoriasis-diverse-skin-tones

Jennifer Soung, MD, and Mona Shahriari, MD, discuss trust-building, psychosocial burden, and treatment fit in psoriasis care for diverse skin tones.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Iliyan D. Iliev, PhD is a professor of immunology in medicine and co-director of the microbiome core laboratory at the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine

Gut fungal dysbiosis has been implicated in

, yet strategies for targeting the intestinal mycobiota remain unexplored.¹ Iliyan D. Iliev, PhD, is professor of immunology in medicine and co-director of the microbiome core laboratory at the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine. He led a new prospective observational study testing whether clearing intestinal Candida could reshape the gut microbiome and disease activity in patients with IBD and oral thrush.

His laboratory has previously shown some Candida albicans strains produce candidalysin, a toxin damaging epithelial and immune cells, linked to impaired intestinal healing and response to therapy in mouse models and patient association studies.²

Investigators compared a topical nystatin rinse (n = 18) with systemic fluconazole (n = 35) in 53 patients with mild-to-moderate ulcerative colitis or Crohn disease and oral thrush treated as part of routine care.¹ Fluconazole, but not nystatin, reduced intestinal Candida burden, increased bacterial diversity, and expanded short-chain fatty acid-producing taxa in the gut.¹ Fluconazole was also associated with improved disease activity indices, measured by the partial Mayo score and Harvey-Bradshaw Index, and a decreased risk of disease progression over 8 weeks.¹

"These results highlight the potential of microbiome-based approaches to restore a balanced microbial community in the gut," said Iliev.³ The study was not randomized or placebo-controlled, and a placebo-controlled trial with longer follow-up and endoscopic data is needed to confirm the findings. In the following interview, Iliyan D. Iliev, PhD, discusses the mechanism linking Candida to intestinal inflammation, the disease activity findings, and the trial needed to confirm antifungal cotherapy in IBD.

Q&A: Fluconazole, Candida, and the Gut Microbiome in IBD

HCPLive: What were you and your co-investigators trying to understand about the gut microbiome in patients with IBD?

Iliyan Iliev, PhD: I'm Iliyan Iliev, and I'm a professor of immunology at Weill Cornell Medical College. We are very interested in the mucosal immune response in the intestines, and we have been working for many years on an interesting part of the intestinal microbiota, the mycobiome, or the fungal communities. 

This became very relevant in the context of inflammatory bowel disease because we observed in our patients an expansion of specific fungal species, particularly Candida albicans. Other groups have also shown other members of the mycobiome expanding in the intestines of these patients. We started asking what those species are doing there, and whether there is anything causative happening in the intestine. We studied the immune response and different mediators, and what turned out, in a nutshell, is that those species of Candida albicans are transferred. They are very common in our community, they live in our intestines, and they expand in those patients. 

Some of those strains have the ability to produce a toxin called candidalysin, and it drills holes in the epithelial cells and in other inflammatory immune cell populations. What that leads to, we found, is that those cells start producing inflammatory mediators, thinking an infection is happening, and they try to fight the microbe, which leads to increased inflammation. We found this in different mouse models, and we also did association studies in patients showing it actually influences intestinal healing and sometimes even the response to therapy. That study took a long time because the design was very important. We had enough evidence to look at how the treatment would affect the patient population, but not enough to design a placebo-controlled clinical trial. So we explored more what was happening in those patients, and we saw that some of them developed mild candidiasis in their mouth, called oral thrush. We started looking into it more deeply, and it became something very interesting. We started tracking those strains. We have technologies in the lab that can isolate strains from the gut and from the oral mucosa and see if they are the same, and it turned out they are. This brought the idea that some of those strains are transferring from the oral mucosa to the gut, and we know they produce that toxin. So what will happen if we target them? 

We designed this study to target Candida in both situations. The patients receive antifungals to control the thrush, and it happens that they are IBD patients. Some of them are treated with nystatin, so they wash their mouth and clear the Candida with nystatin twice a day for two weeks. They clear Candida in their mouth. But what we found is they don't clear it in the gut. Once it seeds the gut, it stays there. The other patients are prescribed fluconazole, which also has a systemic effect. It clears Candida in the oral cavity, and we found it also clears Candida in the gut. So we had two groups of patients we could follow. We followed them for 8 weeks, and in the fluconazole group, where Candida was cleared in both sites, we started seeing a recovery of the microbiome in the gut. In IBD, the diversity of the healthy gut community drops, but after fluconazole treatment, the community started recovering its diversity. Species associated with a healthy gut also started repopulating the gut. 

Most importantly, they started producing metabolites known to be important for intestinal healing, such as butyrate. We also looked at some bile acids. We started seeing this recovery after we cleaned the intestinal Candida, but not when we cleaned only the oral Candida with nystatin. This brought us to the conclusion that removing the Candida species that are expanding can lead to some recovery. We cannot tell if it is indirect, meaning you clean the Candida, inflammation subsides, and that is why you have the bacterial recovery. Since this was a short study, only 8 weeks, there is no standard of care that would perform colonoscopy twice in that period, before and after. So we did not have that data, but we had the clinical scores. 

We had patients with ulcerative colitis, using the Mayo score, and patients with Crohn disease, using the Harvey-Bradshaw Index, and in both situations we saw clinical improvement. This brought us to the hypothesis that removing the Candida species producing the toxin may lead to a better situation, where you slightly recover from the inflammatory effect of the strains.

HCPLive: What do the disease activity improvements show, and what are the clinical implications?

Iliyan Iliev, PhD: The disease activity is an interesting angle. Again, we didn't have colonoscopy or biopsies that could be taken in such a short time, so the disease activity was probably the best direction we could go. What we saw in both ulcerative colitis and Crohn disease patients is they reported improvement, so improved disease activity, when they were treated with fluconazole, which removes Candida in the oral cavity and in the gut. 

This brought the hypothesis that this type of treatment is the one that leads to some benefits. Of course, to have something conclusive, it has to be a placebo-controlled study, and we probably need other angles that will assess, in the long term, whether the patients can be evaluated again in six months or so, and collect colonoscopy data as well. Then we will have a good idea if this is a long-term effect and if it's clinically meaningful. But for that, it has to be a placebo-controlled study. However, in a situation where you start something new, this is the first step, and it's very important to have that first step. It's 53 patients that we could assess here.

HCPLive: What would need to happen before targeted antifungal therapy could become part of how clinicians manage IBD?

Iliyan Iliev, PhD: I feel the next step is, of course, a placebo-controlled clinical trial. Antifungal drugs, if you use them very long term, can lead to liver toxicity and so on. They can lead to resistance. So it's not something we would recommend using, or even test that way, to use it for a very long term.

 But in those windows where you have this Candida expansion, that's where we will be targeting. It will be short-term treatment, where we show here it's actually effective, and we do it in a setting where we have the answer of whether this could be a standard of care one day for this subpopulation of patients that experience overgrowth.

HCPLive: Was there anything else you wanted to highlight or add about the study?

Iliyan Iliev, PhD: It's something we have been working on for many years. Mechanistically, it's very interesting because we're learning more and more that fungal species living on our body can do a lot to our normal physiology, but there is a very fine line. People call it dysbiosis. I would call it expansion of those populations. 

They find an environment where they will actually grow uncontrollably, and then the immune system reacts to that. It sees there is this growth, and it tries to compensate, and that's where we have these more pathological situations. But as commensals, it's very interesting to study how fungal species and also some bacterial species have an important role in immune system development and in our health overall.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Pan X, Conroy A, Ngima TS, et al. Antifungal therapy improves microbiome dynamics in inflammatory bowel disease. Nat Med. 2026;32(9):3385-3395. doi:10.1038/s41591-026-04616-y

Li XV, Leonardi I, Putzel GG, et al. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature. 2022;603(7902):672-678. doi:10.1038/s41586-022-04502-w

Weill Cornell Medicine. Antifungal therapy shows potential for IBD patients with candida overgrowth. Published September 1, 2026. Accessed September 23, 2026. 

https://www.eurekalert.org/news-releases/1142314

Candida overgrowth in IBD may be mechanistically linked to inflammation via candidalysin-mediated epithelial injury and downstream immune activation, with evidence of oral-to-gut strain transfer. In a prospective observational cohort of 53 patients with mild-to-moderate UC or Crohn disease plus oral thrush, systemic fluconazole—unlike topical nystatin—reduced intestinal Candida burden, increased bacterial diversity, and enriched short-chain fatty acid–producing taxa. Fluconazole use correlated with improved partial Mayo and Harvey–Bradshaw scores and lower 8-week progression risk, warranting randomized, endoscopy-informed validation.

Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Manish Wadhwa, MD, is a cardiologist and electrophysiologist with San Diego Arrhythmia Associates and the chief executive officer of SummaCor.

As AI continues to evolve at a breakneck pace, catch up on some of the ways it’s already been implemented in cardiovascular care.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Features

An Uncharted Path: How Clinicians are Implementing Artificial Intelligence Across Cardiology

Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Corticosteroid Stewardship in Dermatology is Not Steroid Avoidance, With Adam Friedman, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use 

Andrew J. Cutler, MD, clinical professor of psychiatry at SUNY Upstate Medical University.

Interim ProACt data show adjunctive cariprazine may work within 2 weeks, easing reluctance to augment antidepressant therapy in MDD, Andrew Cutler, MD, says.

Why Clinicians Should Not Wait to Augment Inadequate Response in MDD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Conference Preview: 2026 EADV Congress in Vienna

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Inaxaplin Cuts Proteinuria in Broader APOL1 Kidney Disease Population

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Tips for Clinicians Diagnosing Patients with Diverse Skin Types

Professor of Medicine at the University of Barcelona

Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Strategic Alliance Partnership

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

George Vasquez-Rios, MD, MSCR, FASN, is a nephrologist and glomerular disease specialist and director of the Glomerular & Genetic Diseases Center.

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of finerenone for CKD with T1D.

Latest News

Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes

Redefining Treatment Success in Achondroplasia Beyond Height

Recognizing the Multisystem Burden of Achondroplasia

Why Trust and Timing Shape Psoriasis Outcomes in Skin of Color

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD